Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Arrowhead Pharmaceuticals Earns $100M Milestone Payment From Sarepta Therapeutics, Triggered When Arrowhead Reached The First Of Two Prespecified Enrollment Targets And Subsequent Authorization To Dose Escalate In A Phase 1/2 Study Of ARO-DM1 For Type 1 Myotonic Dystrophy

Author: Benzinga Newsdesk | July 28, 2025 07:37am

Arrowhead currently expects to achieve the second enrollment target by the end of 2025, which would trigger an additional $200 million milestone payment from Sarepta

Posted In: ARWR SRPT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist